Haemonetics Corp at Raymond James Institutional Investors Conference Transcript
All right. We're about a minute over, so I figure we'd get started. Welcome. I'm Andrew Cooper, the diagnostics and life science tools analyst here at Raymond James. We're happy to have Haemonetics joining us, CEO right here. We've got IR and audience as well. And I'm going to pass it over to Chris to start us off, with just a little bit of an overview, tell us a little bit about who Haemonetics is, and get us rolling this morning.
Great. Thanks, Andrew, and thank you all for joining. Great to be here. Normal Safe Harbor comments upfront, just to make sure we're all on the same page there in kind of forward-looking views. So when you think about Haemonetics, the company I joined almost six years ago now, I'll kind of articulate what we do and how we approach it in a simple 3 by 3, which is we have three very distinct businesses, what we call plasma, blood center, and hospital. The first two are very much involved in collections,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |